IN8bio, Inc.INABNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-15.3%
5Y CAGR+15.2%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-15.3%/yr
vs +94.2%/yr prior
5Y CAGR
+15.2%/yr
Recent deceleration
Acceleration
-109.5pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$17.36M-43.0%
2024$30.44M+9.3%
2023$27.84M-2.4%
2022$28.52M+94.6%
2021$14.65M+71.2%
2020$8.56M+68.9%
2019$5.07M+152.8%
2018$2.00M-